





United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/040,128

01/02/2002

Fang Liao

11245/75

26646 KENYON & KENYON ONE BROADWAY NEW YORK, NY 10004



CONFIRMATION NO. 8763
FORMALITIES LETTER
OC0000000007445182

Date Mailed: 02/08/2002

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:






- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



SM

Application Number 10/040,128

January 2, 2002

Examiner To Be Assigned Art Unit 1614

Invention Title

ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY

Inventor(s)

LIAO, et al.

Address to:

Commissioner for Patents Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

Date: March 29, 2002

with M. Willion Signature: Elizabeth M. Wieckowski (Reg. No. 42,226)

In response to the Notice to File Corrected Application Papers mailed February 8, 2002, a copy of which is enclosed, applicants submit herewith the following:

Nine (9) sheets of Substitute Drawings which are believed to comply with the requirements of 37 CFR 1.84(g) and which are to be substituted for the drawings as originally filed. Two (2) pages of Sequence Listings in written form, one (1) diskette containing the same Sequence Listing in Computer Readable format and a Sequence Statement Under 37 C.F.R. §1.821(f) and §1.821(g).

It is respectfully submitted that no fee is required. However, if any fee is required, the Commissioner is hereby authorized to charge fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: March 29, 2002

By:

Winstth M. Williams

Elizabeth M. Wieckowski (Reg. No. 42,226)

KENYON & KENYON

One Broadway

New York, N.Y. 10004 (212) 425-7200 (telephone)

(212) 425-5288 (facsimile)